A Review of the Pharmacokinetics of Abacavir
@article{Yuen2008ARO, title={A Review of the Pharmacokinetics of Abacavir}, author={G. Yuen and S. Weller and G. Pakes}, journal={Clinical Pharmacokinetics}, year={2008}, volume={47}, pages={351-371} }
Abacavir is a carbocyclic 2′-deoxyguanosine nucleoside reverse transcriptase inhibitor that is used as either a 600-mg once-daily or 300-mg twice-daily regimen exclusively in the treatment of HIV infection. Abacavir is rapidly absorbed after oral administration, with peak concentrations occurring 0.63–1 hour after dosing. The absolute bioavailability of abacavir is approximately 83%. Abacavir pharmacokinetics are linear and doseproportional over the range of 300–1200 mg/day. To date, one study… CONTINUE READING
Topics from this paper
Paper Mentions
Blog Post
102 Citations
The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women
- Medicine
- AIDS
- 2016
- 6
Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
- Medicine
- Antiviral therapy
- 2010
- 22
- PDF
Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
- Medicine
- Journal of virus eradication
- 2015
Population pharmacokinetics of abacavir in infants, toddlers and children.
- Medicine
- British journal of clinical pharmacology
- 2013
- 12
Bioequivalence study of abacavir 300 mg tablets in healthy Thai male volunteers under fasting conditions
- Medicine
- 2014
- Highly Influenced
Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2020
Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV
- Medicine
- Advances in therapy
- 2010
- 15
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection
- Medicine
- Expert opinion on drug safety
- 2015
- 12
References
SHOWING 1-10 OF 88 REFERENCES
Pharmacokinetics of Abacavir in HIV-1-Infected Patients with Impaired Renal Function
- Medicine
- Nephron
- 2001
- 29
Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children
- Medicine
- Antimicrobial Agents and Chemotherapy
- 1999
- 52
- PDF
Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults
- Medicine
- Antimicrobial Agents and Chemotherapy
- 2000
- 47
- PDF
Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
- Medicine
- Antimicrobial Agents and Chemotherapy
- 2001
- 90
- PDF
Safety and Pharmacokinetics of Abacavir (1592U89) following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults
- Medicine
- Antimicrobial Agents and Chemotherapy
- 1999
- 56
- PDF
Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects
- Medicine
- Antimicrobial Agents and Chemotherapy
- 2000
- 69
- PDF
A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection
- Medicine
- Pediatrics
- 1999
- 39
- PDF
Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection
- Medicine
- Antimicrobial Agents and Chemotherapy
- 1999
- 60
- PDF
Methadone Blood Concentrations Are Decreased by the Administration of Abacavir Plus Amprenavir
- Chemistry, Medicine
- Therapeutic drug monitoring
- 2001
- 54
Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System
- Medicine
- Antimicrobial Agents and Chemotherapy
- 2002
- 32
- PDF